India, Aug. 13 -- Evotec SE (EVO), the Hamburg-based drug discovery and development company, reported financial results for the second quarter and first half of 2026, highlighting revenue growth and expanding partnerships compared with the prior year, reflecting lower revenues and profitability compared with the prior year, while highlighting growing commercial momentum in its base business.
Second Quarter 2026 Results
Group revenues of €143.5 million compared to €171.2 million in Q2 2025, representing a 16.2% decline year-on-year.
Adjusted Group EBITDA was -€20.8 million, compared with -€5.0 million in the prior-year quarter, reflecting weaker contributions from strategic partnerships.
First Half 2026 Results
F...